PLUS THERAPEUTICS, INC.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
CNSY$0.57-11.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and par value data)
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $2,233 | $76 |
| Investments | 4,646 | 3,530 |
| Grant receivable | 1,021 | 571 |
| Other current assets | 1,314 | 1,082 |
| Total current assets | 9,214 | 5,259 |
| Property and equipment, net | 289 | 448 |
| Operating lease right-use-of assets | 29 | 73 |
| Goodwill | 372 | 372 |
| Intangible assets, net | 401 | 469 |
| Other assets | 45 | 12 |
| Total assets | $10,350 | $6,633 |
| Liabilities and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $6,359 | $11,288 |
| Operating lease liability | 30 | 44 |
| Deferred grant liability | 927 | 927 |
| Line of credit | — | 3,292 |
| Total current liabilities | 7,316 | 15,551 |
| Noncurrent operating lease liability | — | 31 |
| Total liabilities | 7,316 | 15,582 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.001 par value; 2,000,000,000 shares authorized; 92,438,432 shares issued; and 92,180,007 shares outstanding as of June 30, 2025, and 100,000,00 shares authorized; 6,154,758 shares issued; and 5,896,333 shares outstanding as of December 31, 2024, respectively | 92 | 6 |
| Treasury stock (at cost), 258,425 shares as of June 30, 2025 and December 31, 2024, respectively | (500) | (500) |
| Additional paid-in capital | 509,171 | 485,024 |
| Accumulated deficit | (505,729) | (493,479) |
| Total stockholders’ equity (deficit) | 3,034 | (8,949) |
| Total liabilities and stockholders’ equity | $10,350 | $6,633 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.